\s=b\Psychoimmunology, the interrelationship between the brain/mind/psyche and the immune system, is now an established area of scientific research. Based on prior investigations we hypothesized that an experienced meditator could affect her delayed hypersensitivity reaction by a psychological process. A single-case study design was employed in which the subject was skin tested weekly with varicella zoster skin test reagent. After independently by two readers, one of whom was "blind" to the protocol condition. After the 48-hour reading, blood was obtained for in vitro assay of lymphocyte stimulation by VZ antigen. The phase 2, three-week period served as the intervention period in which the subject was asked to use whatever mechanism she thought would be helpful to modulate or reduce her skin test response. She was asked not to take medicines during this time, specifically no steroids, and was asked to inform us if she became ill in any way. Her skin tests were read and blood samples were obtained on a weekly basis j ust as during the baseline study. Phase 3 served as a return to baseline, in which she was instructed to allow her skin test to react in an unmodulated fashion for each of three weeks.
\s=b\Psychoimmunology, the interrelationship between the brain/mind/psyche and the immune system, is now an established area of scientific research. Based on prior investigations we hypothesized that an experienced meditator could affect her delayed hypersensitivity reaction by a psychological process. A single-case study design was employed in which the subject was skin tested weekly with varicella zoster skin test reagent. After baseline immunologic studies, she was able, as hypothesized, to significantly reduce both the induration of her delayed hypersensitivity skin test reaction and in vitro lymphocyte stimulation to varicella zoster. Then, as predicted, she was able to allow her reaction to return to baseline. As a confirmation of what is to our knowledge this previously undescribed phenomenon, she was able to reproduce the entire sequence nine months later. It appears that this subject can independently by two readers, one of whom was "blind" to the protocol condition. After the 48-hour reading, blood was obtained for in vitro assay of lymphocyte stimulation by VZ antigen. The phase 2, three-week period served as the intervention period in which the subject was asked to use whatever mechanism she thought would be helpful to modulate or reduce her skin test response. She was asked not to take medicines during this time, specifically no steroids, and was asked to inform us if she became ill in any way. Her skin tests were read and blood samples were obtained on a weekly basis j ust as during the baseline study. Phase 3 served as a return to baseline, in which she was instructed to allow her skin test to react in an unmodulated fashion for each of three weeks.
Nine months after the first study period, the subject was studied again with the same protocol. All skin tests used the Mantoux technique with tuberculin syringes and 25-gauge needles. Tests were read using the ballpoint pen technique described by Sokal.4 All readings were in millimeters.
Varicella zoster virus antigen was prepared from the Scott strain of VZ and human diploid cells as reported by Steele and 
RESULTS
The subject remained healthy throughout both study periods. There was high interrater reliability between the two skin-test readers (Pearson's correlation coefficient = .86). Figure 1 represents the induration measured at 48 hours for each phase. The solid line represents the first study period, the broken line is the second study period, and the heavy line is the mean.
For lymphocyte stimulation assays, control cultures (me¬ dium alone) averaged 2,641 ± 798 cpm and had no significant influence on calculation of the blastogenic index. Changes for the optimal concentration of antigen in all cases were representative of changes seen with other VZ antigen concentrations in the dose-response curve. Therefore, for simplicity, data are presented using the mean blastogenic index with optimal VZ antigen concentrations for the study periods. Figure 2 represents \s=b\ Despite diffuse disease of the lungs (often with widespread inflammation or obliteration of blood vessels) in sarcoidosis, pulmonary hypertension is uncommon, occurring in 1% to 4% of cases. We report a case of sarcoidosis and severe pulmonary hypertension that, in striking contrast to other reports, occurred in the absence of obliterative pulmonary vascular disease. We therefore examined the possibility of whether an abnormality in pulmonary vascular tone might be a cause of the pulmonary hypertension. In pharmacologic studies, we demonstrated pulmonary vasodilatation and, in response to increased pulmonary blood flow, the elaboration of the pulmonary vasoconstricting eicosanoid, thromboxane.
( (Figure) . The parenchyma was studded with small to medium-sized noncaseating granulomas that did not involve blood vessels. Medial hypertrophy, slight mural fibrosis, and fibromuscular proliferation were present in the pulmonary arteries. Pulmonary hypertensive lesions were focal and grade 1 to 3 on the Heath-Edwards scale. There was no evidence of fibrosis, vasculitis, thrombosis, or embolism. Micro¬ organisms were not detected.
The stable breakdown products of prostacyclin (6-ket0-PGFlo) and thromboxane A2 (TXB2) were measured by radioimmunoassay using commercially available kits. The patient's peripheral venous plasma TXB2 was 60 pg/mL (laboratory normal, <80 pg/mL) and 6-keto-PGFla was 130 pg/mL (laboratory normal, =s80 pg/mL). A detailed study of pulmonary vasoreactivity and vasoactive medi¬ ators was performed during repeated cardiac catheterization.
Administration of epoprostenol (prostacyclin), nitroglycerin, and nifedipine demonstrated that vasodilatation of the pulmonary vascular bed could be induced (Table) . An increase in the concen¬ tration of TXB2 was detected from the pulmonary artery to the aorta, concomitant with the increase in flow seen with administra¬ tion of epoprostenol, nitroglycerin, and nifedipine, suggestive of pulmonary production of thromboxane A2 (TXA2). No transpulmonary gradient of 6-keto-PGFla was detected during adminis¬ tration of nitroglycerin or nifedipine.
Despite treatment with prednisone (1 mg/kg/day) for two months, the patient developed progressive right ventricular fail¬ ure. In an attempt to reverse her rapidly deteriorating condition, nifedipine and cyclophosphamide were added; she died two weeks later.
COMMENT
Pulmonary hypertension is an unusual but well-recog¬ nized complication of sarcoidosis. Rizzato and co-workers4
